Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Ann Oncol 2018; 29(8): 1843–1852 (doi: 10.1093/annonc/mdy229) In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialAnnals of OncologyVol. 29Issue 8PreviewBevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Full-Text PDF Open Access